Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-BC)

Last updated: September 17, 2024
Sponsor: University of Alabama at Birmingham
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Insomnia

Cancer

Treatment

transauricular Vagus Nerve Stimulation

Clinical Study ID

NCT06006299
IRB-300010460
  • Ages > 18
  • Female

Study Summary

In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. at least 18 years of age

  2. diagnosed stage I-IV breast cancer

  3. self-reported difficulty falling asleep, staying asleep, or waking up too early, forat least three nights per week for a duration of at least three months

  4. beginning or worsening of sleep disturbance since cancer diagnosis (did your sleepproblems begin or get worse with the diagnosis of cancer or with chemotherapy?)

  5. English-speaking

Exclusion

Exclusion Criteria:

  1. Are using a daily sleep aid except melatonin (use of a sleep aid as needed will bepermitted, and use will be noted).

  2. have a history of severe mental illness

  3. have an implanted medical device of any type

  4. have a history of seizures

  5. have peripheral neuropathy including temporal mandibular disorders and Bells Palsy

  6. have vasovagal syncope

  7. have moderate to severe cognitive impairment

  8. have <6 months to live as determined by the physician

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: transauricular Vagus Nerve Stimulation
Phase:
Study Start date:
September 26, 2023
Estimated Completion Date:
December 31, 2025

Study Description

The study will evaluate the feasibility, safety, and tolerability of nightly, at-home self-administered taVNS treatments. Study staff will monitor for adverse reactions, unanticipated adverse device events and severe adverse events as described to evaluate safety, tolerability, and biocompatibility. Additionally, investigators will estimate effect size by collecting outcome assessment data as described below. An additional objective is to use information gained through this study to inform product development activities. Specific information about the comfort, ease of use, and other user subject feedback will be used to inform future product development efforts for optimizing device designs.

Specific Aim 1: To evaluate the feasibility of using taVNS for patients with breast cancer to treat insomnia. HYPOTHESIS: Investigators expect that 40 patients with stage I-III breast cancer and insomnia will be enrolled and undergo taVNS to address insomnia, quantified by various sleep related outcome measures, with an estimated recruitment rate of 70%, eligibility rate of 70%, completion rate of 80%, and follow up rate of 80%.

Specific Aim 2: To evaluate the efficacy of repeated, nightly taVNS on sleep quality, anxiety, and cancer related fatigue. HYPOTHESIS: Investigators hypothesize that patients will report improved sleep, anxiety, depression, and cancer related fatigue after one week of taVNS.

Connect with a study center

  • UAB Lakeshore Collaborative (WHARF)

    Birmingham, Alabama 35209
    United States

    Active - Recruiting

  • UAB Spain Rehabilitation Center

    Birmingham, Alabama 35233
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.